Company intelligence / Profile preview

Orchard House

London, United Kingdom

Ownership: Private
Employees: ~166
Development stage: Other

Overview

Orchard Therapeutics has developed and commercialized gene therapies for rare genetic diseases. Their lead product, Libmeldy, is approved in the EU for metachromatic leukodystrophy.

Therapeutic areas: ImmunologyNeurologyRare DiseasesGastroenterology
Modalities: Gene TherapyStem Cell Therapy
Industry: Biotech

Partnerships

University College LondonGreat Ormond Street HospitalUniversity of ManchesterUniversity of California Los AngelesBoston Children’s Hospital

Beyond the preview

Go deeper on Orchard House.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orchard House.

Explore the full profile